Helen Heffernan | |
---|---|
Awards | Companion of the New Zealand Order of Merit |
Academic background | |
Alma mater | University of Otago |
Academic work | |
Institutions | Institute of Environmental Science and Research |
Helen Mary Heffernan CNZM is a New Zealand microbiologist,specialising in antibiotic resistance. In 2020 she was appointed a Companion of the New Zealand Order of Merit for services to health. The Institute of Environmental Science and Research awarded Heffernan their Lifetime Achievement Award in 2018.
Heffernan has a Bachelor of Science with Honours from the University of Otago. [1] [2] Heffernan worked at New Zealand's National Health Institute and the Institute of Environmental Science and Research (ESR),a Crown Research Institute. [3]
Heffernan's research involved the development of cold chain standards,which are important for the safe management and storage of vaccines. [3] She also carried out surveillance for infectious diseases,allowing the rate of spread of antimicrobial resistance to be slowed. [4] Heffernan's research was the basis for vaccine programmes against haemophilus influenzae type b,pneumococcus and meningococcus. [3]
Heffernan was a member a number of national committees,including the National Antimicrobial Committee,the Ministry for Primary Industries' Technical Advisory Group,the Ministry of Health's Pneumococcal Surveillance Advisory Group. [4] She spoke about New Zealand's place in the 'global antimicrobial crisis' at the One Health symposium in 2017. [5] She also represented New Zealand at regional meetings in the Pacific,and at the World Health Organisation's workshop on Antimicrobial Resistance Surveillance. [3] [4]
In the 2020 New Year's Honours Heffernan was appointed a Companion of the New Zealand Order of Merit,for services to health. [4] On her appointment,Heffernan asked New Zealanders to play their part to reduce antibiotic resistance,saying "While antibiotics are essential medicines to treat bacterial infections,we overuse and misuse them and this contributes to resistance." [3] On her retirement in 2018,after a 43 year career,ESR awarded Heffernan their Lifetime Achievement Award. [6]
Antimicrobial resistance (AMR) occurs when microbes evolve mechanisms that protect them from the effects of antimicrobials. All classes of microbes can evolve resistance to the point that one or more drugs used to fight them are no longer effective. Fungi evolve antifungal resistance, viruses evolve antiviral resistance, protozoa evolve antiprotozoal resistance, and bacteria evolve antibiotic resistance. Together all of these come under the umbrella of antimicrobial resistance.
Methicillin-resistant Staphylococcus aureus (MRSA) is a group of gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. It caused more than 100,000 deaths worldwide attributable to antimicrobial resistance in 2019.
Clindamycin is a lincosamide antibiotic medication used for the treatment of a number of bacterial infections, including osteomyelitis (bone) or joint infections, pelvic inflammatory disease, strep throat, pneumonia, acute otitis media, and endocarditis. It can also be used to treat acne, and some cases of methicillin-resistant Staphylococcus aureus (MRSA). In combination with quinine, it can be used to treat malaria. It is available by mouth, by injection into a vein, and as a cream or a gel to be applied to the skin or in the vagina.
Fusidic acid, sold under the brand name Fucidin among others, is a steroid antibiotic that is often used topically in creams or ointments and eyedrops but may also be given systemically as tablets or injections. As of October 2008, the global problem of advancing antimicrobial resistance has led to a renewed interest in its use.
Vancomycin-resistant Staphylococcus aureus (VRSA) are strains of Staphylococcus aureus that have acquired resistance to the glycopeptide antibiotic vancomycin. Bacteria can acquire resistant genes either by random mutation or through the transfer of DNA from one bacterium to another. Resistance genes interfere with the normal antibiotic function and allow bacteria to grow in the presence of the antibiotic. Resistance in VRSA is conferred by the plasmid-mediated vanA gene and operon. Although VRSA infections are uncommon, VRSA is often resistant to other types of antibiotics and a potential threat to public health because treatment options are limited. VRSA is resistant to many of the standard drugs used to treat S. aureus infections. Furthermore, resistance can be transferred from one bacterium to another.
The Infectious Diseases Society of America (IDSA) is a medical association representing physicians, scientists, and other healthcare professionals who specialize in infectious diseases. It was founded in 1963 and is based in Arlington, Virginia. As of 2018, IDSA had more than 11,000 members from across the United States and nearly 100 other countries on six different continents. IDSA's purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases. It is a 501(c)(6) organization.
Ceftaroline fosamil (INN), brand name Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. Ceftaroline fosamil is a prodrug of ceftaroline. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. It retains some activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria, but its effectiveness is relatively much weaker. It is currently being investigated for community-acquired pneumonia and complicated skin and skin structure infection.
NDM-1 is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics. These include the antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections. The gene for NDM-1 is one member of a large gene family that encodes beta-lactamase enzymes called carbapenemases. Bacteria that produce carbapenemases are often referred to in the news media as "superbugs" because infections caused by them are difficult to treat. Such bacteria are usually sensitive only to polymyxins and tigecycline.
Staphylococcus pseudintermedius is a gram-positive spherically shaped bacterium of the genus Staphylococcus found worldwide. It is primarily a pathogen for domestic animals, but has been known to affect humans as well. S. pseudintermedius is an opportunistic pathogen that secretes immune-modulating virulence factors, has many adhesion factors, and the potential to create biofilms, all of which help to determine the pathogenicity of the bacterium. Diagnoses of S. pseudintermedius have traditionally been made using cytology, plating, and biochemical tests. More recently, molecular technologies like MALDI-TOF, DNA hybridization and PCR have become preferred over biochemical tests for their more rapid and accurate identifications. This includes the identification and diagnosis of antibiotic resistant strains.
Antibiotic use in livestock is the use of antibiotics for any purpose in the husbandry of livestock, which includes treatment when ill (therapeutic), treatment of a group of animals when at least one is diagnosed with clinical infection (metaphylaxis), and preventative treatment (prophylaxis). Antibiotics are an important tool to treat animal as well as human disease, safeguard animal health and welfare, and support food safety. However, used irresponsibly, this may lead to antibiotic resistance which may impact human, animal and environmental health.
Alison Helen Holmes is a British infectious diseases specialist, who is a professor at Imperial College London and the University of Liverpool. Holmes serves as Director of the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance and Consultant at Hammersmith Hospital. Holmes is on the Executive Committee of the International Society of Infectious Diseases, and she serves on a variety of World Health Organization (WHO) expert groups related to antimicrobial use, Antimicrobial Resistance (AMR), infection prevention and sepsis. Her research considers how to mitigate antimicrobial resistance.
Kerry L. LaPlante is an American pharmacist, academic and researcher. She is the Dean at the University of Rhode Island College of Pharmacy. She is a Professor of Pharmacy and former department Chair of the Department of Pharmacy Practice at the University of Rhode Island, an adjunct professor of medicine at Brown University, an Infectious Diseases Pharmacotherapy Specialist, and the Director of the Rhode Island Infectious Diseases Fellowship and Research Programs at the Veterans Affairs Medical Center in Providence, Rhode Island.
David R. Murdoch is a New Zealand academic specialising in paediatric infectious diseases, especially pneumonia. He has also worked on Legionnaires' disease and has advised the Oxford University vaccine group and the New Zealand government on COVID-19. Murdoch served as Vice-Chancellor of the University of Otago between February 2022 and June 2023.
Jackie Benschop is a New Zealand Professor of Veterinary Public Health at Massey University, specialising in the animal–human–environment interface, particularly for Leptospira, Campylobacter and Salmonella. She is a member of the World Health Organisation's Steering Committee for the Global Leptospirosis Environmental Action Network, and a co-founder of the African Leptospirosis Network.
Ruth Catherine Massey is an Irish molecular biologist who is a professor at University College Cork. Her research considers pathogens. She was elected to the European Molecular Biology Organization in 2023.
Catherine Ann Byrnes is a New Zealand academic paediatrician, and is a full professor at the University of Auckland, specialising in respiratory disease in children, including cystic fibrosis and infectious diseases.
Natalie Joan Gauld is a New Zealand pharmacist, lecturer and researcher. She was appointed an Officer of the New Zealand Order of Merit for services to pharmacy and health in 2023.
Louise Frances Basford Nicholson is a New Zealand neuroscientist, and is professor emerita at the University of Auckland, specialising in molecular mechanisms common to neurodegenerative diseases. In 2021, Nicholson was appointed a Companion of the New Zealand Order of Merit for services to neuroscience and education.
Helen Stapylton Timperley is a New Zealand education academic, and is professor emerita of education, learning and professional practice at the University of Auckland. In 2010, Timperley was appointed a Companion of the New Zealand Order of Merit, for services to education.
Frances Anne Hughes is a New Zealand nursing academic and leader, and has held senior roles across several nursing organisations. In 2005 Hughes was appointed an Officer of the New Zealand Order of Merit, for services to the mental health profession. In 2020 she was appointed a Companion of the New Zealand Order of Merit for services to nursing and mental health.